Trial reportOncoimmunology2021
Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies.
Trial report in Oncoimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2022Pooled it
- Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial.Cancer communications (London, England) · 2025Trial
- Article
- Organ-metastatic landscape delineates overall and site-specific immune-related adverse events of PD-L1 blockade in advanced NSCLC.NPJ precision oncology · 2026Article
- Stereotactic radiotherapy for brain metastases of non-small cell lung cancer: A comprehensive review.World journal of radiology · 2025Review
- Collaborative assessment of the risk of postoperative progression in early-stage non-small cell lung cancer: a robust federated learning model.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Inhalable metal-organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy.Acta pharmaceutica Sinica. B · 2024Article
- Article
- Determining the prognosis of Lung cancer from mutated genes using a deep learning survival model: a large multi-center study.Cancer cell international · 2023Article
- State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain.Neurosurgical review · 2022Review
- ACT001 inhibits the proliferation of non-small cell lung cancer cells by upregulating NKTR expression.Thoracic cancer · 2022Article
- Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.BMC medicine · 2022Article
- Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.Frontiers in immunology · 2022Review
- The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis.Frontiers in immunology · 2022Article
- The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.Applied bionics and biomechanics · 2022Article
- Article
- Outcomes of Combined Atezolizumab Plus Chemotherapy in Non-small Cell Lung Cancer Patients in Clinical Practice.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.